BioNTech SE (BNTX) Reports Q4 EPS of EUR1.08; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Six killed in cyclone off India's eastern coast
- Rivian shares slip ahead of Thursday earnings release
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
BioNTech (BNTX) PT Lowered to $151 at Truist Securities
March 11, 2025 11:46 AM EDTTruist Securities analyst Asthika Goonewardene lowered the price target on BioNTech (NASDAQ: BNTX) to $151.00 (from $172.00) while maintaining a Buy rating.
The analyst comments "BNTX's reported 4Q24 revenues of 1.19B was ~6% above consensus, but a bigger focus was the FY25 guidance, most notably the significantly... More
Jefferies Reiterates Buy Rating on BioNTech (BNTX)
March 10, 2025 2:23 PM EDTJefferies analyst Akash Tewari reiterated a Buy rating and $149.00 price target on BioNTech (NASDAQ: BNTX).
The analyst comments "Bottom line: BTNX reported an ok Q - Q4 revs ~1.19B vs 1.18B cons & EPS 1.08 vs 0.77 cons driven by lower Opex. That said, BNTX traded down... More



